Nozue 2008.

Methods	8‐Week wash‐out period 12‐Week randomised study
Participants	17 men and women with heterozygous FH; TC > 230 mg/dL (5.95 mmol/L) 9 participants received atorvastatin, 8 received pitavastatin Atorvastatin baseline TC: 8.22 mmol/L (318 mg/dL) Atorvastatin baseline LDL‐C: 6.05 mmol/L (234 mg/dL) Atorvastatin baseline HDL‐C: 1.60 mmol/L (62 mg/dL) Atorvastatin baseline TG: 1.59 mmol/L (141 mg/dL)
Interventions	Atorvastatin 10 mg/d for 0 to 12 weeks Pitavastatin 2 mg/d for 0 to 12 weeks
Outcomes	Per cent change from baseline at 4 to 12 weeks of serum TC, LDL‐C, HDL‐C and TG
Notes	Atorvastatin group was analysed                 SDs were imputed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable
Allocation concealment (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data on all participants were reported
Selective reporting (reporting bias)	Low risk	All lipid parameters were measured
Other bias	Unclear risk	No source of funding was provided